Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
May 5, 2021
Brian J. Boyarsky, MD, PhD1; William A. Werbel, MD2; Robin K. Avery, MD2; Aaron A. R. Tobian, MD, PhD3; Allan B. Massie, PhD1; Dorry L. Segev, MD, PhD1; Jacqueline M. Garonzik-Wang, MD, PhD1
The goal of this study was to explore the antibody response in individuals with solid organ transplants after their second SARS-CoV-2 vaccine dose in the United States. Eligible participants were those who completed the 2-dose mRNA vaccine and had no previous polymerase chain reaction-confirmed COVID-19. Results show that of the 658 participants, 98 (15%) participants had an antibody response after 1 dose and after two doses, 357 had a response (54%). After receiving the first dose, 259 (39%) had no response, but once they received the second dose, they had a successful response. Although the humoral response increased after 2 doses, solid organ transplant recipients remain vulnerable to COVID-19 and additional research is needed to improve vaccine response for this population.
Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. Jama 2021; 22: 5–7.